Serum tumor markers (such as CA15-3 and/or CEA), if initially elevated, may be helpful in monitoring response, particularly in the case of nonmeasurable disease. However, a change in tumor markers alone should not be used as the only determinant for treatment decisions
Establishing and localizing disease sites as a cause for elevated serum markers (e.g., colorectal, thyroid, ovarian, cervix, melanoma, breast, and germ-cell tumours)
CA15-3 and CEA are the most useful serum markers in patients with breast cancer. Serial determinations of these markers are useful in assessing prognosis, early detection of relapse (metastasis), and therapy monitoring